Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Apr;31(4):551–557. doi: 10.1128/aac.31.4.551

Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration.

E J Bow, E Rayner, B A Scott, T J Louie
PMCID: PMC174776  PMID: 3300532

Abstract

Eighty-four cancer patients at risk of infection because of neutropenia were randomized to receive nalidixic acid as an alternative to trimethoprim-sulfamethoxazole (TMP-SMX) for infection prophylaxis. Infections were documented significantly earlier and more often among patients who entered the trial with neutrophil counts of less than 0.1 X 10(9)/liter. TMP-SMX recipients experienced fewer microbiologically documented infections and bacteremias and were free of infection for a higher proportion of days with severe neutropenia (less than 0.1 X 10(9)/liter) than nalidixic acid recipients. Gram-negative bacillary and Staphylococcus aureus infections accounted for the major differences. Although the majority of aerobic gram-negative bacilli were eliminated from the feces after 1 week of prophylaxis with either agent, TMP-SMX was proved superior to nalidixic acid in this regard and was associated with acquired drug resistance by gram-negative bacilli less frequently. Both agents selected for colonization and subsequent infection by gram-positive cocci. Our data suggest that prophylaxis is most likely to be effective if administered to patients for at least 1 week before they become severely neutropenic. Nalidixic acid used as a single agent in doses of 4 g daily, however, cannot be recommended as an alternative to TMP-SMX for infection prophylaxis in neutropenic cancer patients.

Full text

PDF
551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau G., Belanger P. M. Pharmacokinetics of nalidixic acid in old and young volunteers. J Clin Pharmacol. 1982 Oct;22(10):490–496. doi: 10.1002/j.1552-4604.1982.tb02640.x. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N., Thornsberry C., Ayers L. W., Gerlach E. H., Sommers H. M. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother. 1984 May;25(5):633–637. doi: 10.1128/aac.25.5.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  4. Bow E. J., Louie T. J., Riben P. D., McNaughton R. D., Harding G. K., Ronald A. R. Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am J Med. 1984 Feb;76(2):223–233. doi: 10.1016/0002-9343(84)90777-0. [DOI] [PubMed] [Google Scholar]
  5. Buchanan A. G., Riben P. D., Rayner E. N., Parker S. E., Ronald A. R., Louie T. J. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med. 1985;8(2):139–147. [PubMed] [Google Scholar]
  6. Dekker A. W., Rozenberg-Arska M., Sixma J. J., Verhoef J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia. Ann Intern Med. 1981 Nov;95(5):555–559. doi: 10.7326/0003-4819-95-5-555. [DOI] [PubMed] [Google Scholar]
  7. Dudley M. N., Levitz R. E., Quintiliani R., Hickingbotham J. M., Nightingale C. H. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother. 1984 Dec;26(6):811–814. doi: 10.1128/aac.26.6.811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Enno A., Catovsky D., Darrell J., Goldman J. M., Hows J., Galton D. A. Co-trimoxazole for prevention of infection in acute leukaemia. Lancet. 1978 Aug 19;2(8086):395–397. doi: 10.1016/s0140-6736(78)91865-2. [DOI] [PubMed] [Google Scholar]
  9. Estey E., Maksymiuk A., Smith T., Fainstein V., Keating M., McCredie K. B., Freireich E. J., Bodey G. P. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. Arch Intern Med. 1984 Aug;144(8):1562–1568. doi: 10.1001/archinte.144.8.1562. [DOI] [PubMed] [Google Scholar]
  10. Feld R., Louie T. J., Mandell L., Bow E. J., Robson H. G., Chow A., Belch A., Miedzinski L., Rachlis A., Pater J. A multicenter comparative trial of tobramycin and ticarcillin vs moxalactam and ticarcillin in febrile neutropenic patients. Arch Intern Med. 1985 Jun;145(6):1083–1088. [PubMed] [Google Scholar]
  11. Figueredo A. T., Hryniuk W. M., Strautmanis I., Frank G., Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985 Jan;3(1):54–64. doi: 10.1200/JCO.1985.3.1.54. [DOI] [PubMed] [Google Scholar]
  12. Gualtieri R. J., Donowitz G. R., Kaiser D. L., Hess C. E., Sande M. A. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med. 1983 Jun;74(6):934–940. doi: 10.1016/0002-9343(83)90785-4. [DOI] [PubMed] [Google Scholar]
  13. Guiot H. F., van den Broek P. J., van der Meer J. W., van Furth R. Selective antimicrobial modulation of the intestinal flora of patients with acute nonlymphocytic leukemia: a double-blind, placebo-controlled study. J Infect Dis. 1983 Apr;147(4):615–623. doi: 10.1093/infdis/147.4.615. [DOI] [PubMed] [Google Scholar]
  14. Guiot H. F., van der Meer J. W., van Furth R. Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis. 1981 May;143(5):644–654. doi: 10.1093/infdis/143.5.644. [DOI] [PubMed] [Google Scholar]
  15. Gurwith M. J., Brunton J. L., Lank B. A., Harding G. K., Ronald A. R. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med. 1979 Feb;66(2):248–256. doi: 10.1016/0002-9343(79)90539-4. [DOI] [PubMed] [Google Scholar]
  16. Gurwith M., Truog K., Hinthorn D., Liu C. Trimethoprim-sulfamethoxazole and trimethoprim alone for prophylaxis of infection in granulocytopenic patients. Rev Infect Dis. 1982 Mar-Apr;4(2):593–601. doi: 10.1093/clinids/4.2.593. [DOI] [PubMed] [Google Scholar]
  17. Henry S. A., Armstrong D., Kempin S., Gee T., Arlin Z., Clarkson B. Oral trimethoprim/sulfamethoxazole in attempt to prevent infection after induction chemotherapy for acute leukemia. Am J Med. 1984 Oct;77(4):663–666. doi: 10.1016/0002-9343(84)90359-0. [DOI] [PubMed] [Google Scholar]
  18. Hughes W. T., Kuhn S., Chaudhary S., Feldman S., Verzosa M., Aur R. J., Pratt C., George S. L. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977 Dec 29;297(26):1419–1426. doi: 10.1056/NEJM197712292972602. [DOI] [PubMed] [Google Scholar]
  19. Kauffman C. A., Liepman M. K., Bergman A. G., Mioduszewski J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Reduction of infections and effect on bacterial and fungal flora. Am J Med. 1983 Apr;74(4):599–607. doi: 10.1016/0002-9343(83)91017-3. [DOI] [PubMed] [Google Scholar]
  20. Knothe H. The effect of a combined preparation of trimethoprim and sulphamethoxazole following short-term and long-term administration on the flora of the human gut. Chemotherapy. 1973;18(5):285–296. doi: 10.1159/000221273. [DOI] [PubMed] [Google Scholar]
  21. Louie T. J., Chubb H., Bow E. J., Conly J. M., Harding G. K., Rayner E., James M. Preservation of colonization resistance parameters during empiric therapy with aztreonam in the febrile neutropenic patient. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S747–S761. doi: 10.1093/clinids/7.supplement_4.s747. [DOI] [PubMed] [Google Scholar]
  22. Murray B. E., Rensimer E. R., DuPont H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole. N Engl J Med. 1982 Jan 21;306(3):130–135. doi: 10.1056/NEJM198201213060302. [DOI] [PubMed] [Google Scholar]
  23. Nolan C. M., White P. C., Jr, Feeley J. C., Hambie E. A., Brown S. L., Wong K. H. Vi serology in the detection of typhoid carriers. Lancet. 1981 Mar 14;1(8220 Pt 1):583–585. doi: 10.1016/s0140-6736(81)92033-x. [DOI] [PubMed] [Google Scholar]
  24. Pizzo P. A., Robichaud K. J., Edwards B. K., Schumaker C., Kramer B. S., Johnson A. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr. 1983 Jan;102(1):125–133. doi: 10.1016/s0022-3476(83)80310-2. [DOI] [PubMed] [Google Scholar]
  25. Riben P. D., Louie T. J., Lank B. A., Kornachuk E., Gurwith M. J., Harding G. K., Ronald A. R. Reduction in mortality from gram-negative sepsis in neutropenic patients receiving trimethoprim/sulfamethoxazole therapy. Cancer. 1983 May 1;51(9):1587–1592. doi: 10.1002/1097-0142(19830501)51:9<1587::aid-cncr2820510906>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  26. Ronald A. R., Turck M., Petersdorf R. G. A critical evaluation of nalidixic acid in urinary-tract infections. N Engl J Med. 1966 Nov 17;275(20):1081–1089. doi: 10.1056/NEJM196611172752001. [DOI] [PubMed] [Google Scholar]
  27. Sleijfer D. T., Mulder N. H., de Vries-Hospers H. G., Fidler V., Nieweg H. O., van der Waaij D., van Saene H. K. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer. 1980 Jun;16(6):859–869. doi: 10.1016/0014-2964(80)90140-1. [DOI] [PubMed] [Google Scholar]
  28. Wade J. C., Schimpff S. C., Hargadon M. T., Fortner C. L., Young V. M., Wiernik P. H. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med. 1981 Apr 30;304(18):1057–1062. doi: 10.1056/NEJM198104303041801. [DOI] [PubMed] [Google Scholar]
  29. Wade J. C., Schimpff S. C., Newman K. A., Wiernik P. H. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982 Oct;97(4):503–508. doi: 10.7326/0003-4819-97-4-503. [DOI] [PubMed] [Google Scholar]
  30. Wade J. C., de Jongh C. A., Newman K. A., Crowley J., Wiernik P. H., Schimpff S. C. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. J Infect Dis. 1983 Apr;147(4):624–634. doi: 10.1093/infdis/147.4.624. [DOI] [PubMed] [Google Scholar]
  31. Weiser B., Lange M., Fialk M. A., Singer C., Szatrowski T. H., Armstrong D. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Ann Intern Med. 1981 Oct;95(4):436–438. doi: 10.7326/0003-4819-95-4-436. [DOI] [PubMed] [Google Scholar]
  32. Wilson J. M., Guiney D. G. Failure of oral trimethoprim-sulfamethoxazole prophylaxis in acute leukemia: isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. N Engl J Med. 1982 Jan 7;306(1):16–20. doi: 10.1056/NEJM198201073060105. [DOI] [PubMed] [Google Scholar]
  33. de Jongh C. A., Wade J. C., Finley R. S., Joshi J. H., Aisner J., Wiernik P. H., Schimpff S. C. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. J Clin Oncol. 1983 May;1(5):302–307. doi: 10.1200/JCO.1983.1.5.302. [DOI] [PubMed] [Google Scholar]
  34. van der Waaij D., Berghuis-de Vries J. M. Selective elimination of Enterobacteriaceae species from the digestive tract in mice and monkeys. J Hyg (Lond) 1974 Apr;72(2):205–211. doi: 10.1017/s002217240002341x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES